Literature DB >> 6209077

Biotransformation of the stable prostacyclin analogue, iloprost, in the rat.

W Krause, M Hümpel, G A Hoyer.   

Abstract

The metabolic pathway of the stable prostacyclin analogue, iloprost (ZK 36 374), was studied in the rat, both in vivo and in vitro by a rat liver perfusion model. Metabolites were isolated from both experiments by preparative high performance liquid chromatography and identified by GC/MS and NMR analysis. In vitro, iloprost was metabolized by consecutive beta-oxidation of the upper side chain. Both dinor- and tetranoriloprost could be isolated from the perfusion medium. The metabolic pattern in bile was similar to that in the perfusion medium. In vivo, iloprost was totally metabolized by beta-oxidation of the upper side chain and by subsequent hydroxylation and conjugation. The compounds identified in rat urine were tetranoriloprost which represented about 3/4 of all metabolites, hydroxylated tetranoriloprost with the additional hydroxyl group presumably at position 17 and a conjugate of tetranoriloprost. Dinoriloprost and unchanged drug were not observed. beta-Oxidation of the upper side chain was stereoselective to give a 6 alpha-H/6 beta-H ratio of 86:14.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209077

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.

Authors:  M Hildebrand; T Staks; B Nieuweboer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Pharmacokinetics of nocloprost in human volunteers and its relation to dose.

Authors:  U Tüber; M Brudny-Klöppel; U Jakobs; C Madetzki; M Mahler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

6.  Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.

Authors:  Ralph Theo Schermuly; Christiane Inholte; Hossein Ardeschir Ghofrani; Henning Gall; Norbert Weissmann; Andreas Weidenbach; Werner Seeger; Friedrich Grimminger
Journal:  Respir Res       Date:  2005-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.